Sign in
Create a Profile
Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Diseases and Conditions Researched
Hepatitis B Virus
What is the purpose of this trial?
At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB)
Amendment 7, Part B Sub Study: The primary purpose of this amendment is to obtain preliminary data on the safety of pegylated interferon Lambda (Lambda) when administered in combination with Entecavir(ETV) to patients with hepatitis E antigen-positive (HBeAg-positive) chronic hepatitis B(CHB) infection employing a sequential therapy approach
Participation Guidelines
Gender: Both
Click here for detailed participation information for this trial.
| Sponsor: | Bristol-Myers Squibb |
|---|---|
| Dates: | September 16, 2010 |
| Last Updated: | March 28, 2013 |
| Study HIC#: | 1009007449 |
| Clinicaltrials.gov ID: | NCT01204762 |
How will my information be used?
For more information about this trial, contact:
Joseph Lim
203-737-6063
joseph.lim@yale.edu
Principal Investigator
Joseph K Lim
Internal Medicine
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.
